NCT00096395View on ClinicalTrials.gov

Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

February 28, 2007

Conditions
Recurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer
Interventions
DRUG

gemcitabine hydrochloride

Given IV

DRUG

sorafenib tosylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital Phase 2 Consortium, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00096395 - Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter